AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02564068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment.
Study NCT02027272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
Study NCT02027272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
Study NCT04572685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: A long acting extended release injectable suspension intended for monthly intramuscular administration
Study NCT00186849 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin
Description: See Detailed Description section for details of treatment interventions.
Study NCT00186849 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral Blood Stem Cell Transplant
Description: See Detailed Description section for details of treatment interventions.
Study NCT03664011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 mixed with [C-14]BI 730357 BS
Description: Oral Solution
Study NCT03534713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
Study NCT03534713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
Study NCT02746549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: renal perfusion
Description: measurement of renal perfusion with MRI arterial spin labelling technique
Study NCT01086813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: single dose/IV, bolus over 60secs - infusion over 30 mins
Study NCT04051008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default - use of online grocery shopping platform with default shopping carts
Description: The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
Study NCT04653961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro DSS-MDI algorithm
Description: The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
Study NCT03378232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Olive Oil
Description: Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
Study NCT04111471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics
Description: Enrolled patients will receive 10 grams of inulin daily for 21 days
Study NCT04111471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
Study NCT02317783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Flutemetamol
Description: Brain scan with imaging tracer that binds to amyloid plaques
Study NCT02317783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
Study NCT02317783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Brain scan to assess regions of abnormal volume and density
Study NCT03534713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40mg/m² given once a week during 5 weeks
Study NCT03534713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40mg/m² given once a week during 5 weeks
Study NCT03534713 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
Study NCT03534713 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
Study NCT02731599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treadmill training with cues
Description: 20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
Study NCT02641938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
Study NCT02641938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
Study NCT01102673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
Study NCT01102673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04991532 will be provided
Study NCT03895515 — intervention group
Intervention type: DRUG
Intervention: Fiasp®
Description: Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
Study NCT03037892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, Fentanyl
Description: Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
Study NCT03037892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, Remifentanil
Description: The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
Study NCT03037892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The group 3 patient will receive only Remifentanil in the same doses as given in group
Study NCT04524494 — intervention group
Intervention type: OTHER
Intervention: biopsy of intestinal tissue
Description: 4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
Study NCT04524494 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: 40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
Study NCT04524494 — intervention group
Intervention type: OTHER
Intervention: urine collection
Description: Midstream Urine collection
Study NCT03199404 — intervention group
Intervention type: DEVICE
Intervention: TRAP
Description: Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
Study NCT04562675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LHA intervention
Description: For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
Study NCT04562675 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: brochure-only
Description: brochure-only for control group (CG)
Study NCT03844919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS + CBIT
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10.
Study NCT03844919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS + CBIT
Description: Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
Study NCT03844919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham rTMS + CBIT
Description: Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
Study NCT04008316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine 1mg/day
Study NCT04008316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: colchicine 1mg/day
Study NCT02809989 — intervention group
Intervention type: DRUG
Intervention: Ovaleap®
Description: About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births).
Study NCT03602950 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: autologous PRP will be injected subcutaneously before skin closure at time of elective CS
Study NCT01859559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral intravenous access line placement
Description: The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
Study NCT01859559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Landmark Approach to peripheral intravenous access line placement
Description: ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
Study NCT02348866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: method of laundering and donning scrubs
Study NCT03074656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Description: Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
Study NCT03074656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
Study NCT02190149 — intervention group
Intervention type: BIOLOGICAL
Intervention: ADVATE (Antihemophilic Factor [Recombinant])
Study NCT02190149 — intervention group
Intervention type: BIOLOGICAL
Intervention: RIXUBIS (Coagulation Factor IX [Recombinant])
Study NCT02155504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3700
Description: oral
Study NCT02155504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP3700
Description: oral
Study NCT02155504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: oral
Study NCT02155504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT00706758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS school
Description: Structured patient group education
Study NCT00706758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS-guidebook
Description: Written information - IBS-guidebook
Study NCT05682768 — intervention group
Intervention type: PROCEDURE
Intervention: Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures
Description: Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
Study NCT02795065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
Study NCT02795065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
Study NCT04010136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care training
Description: Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
Study NCT00780104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin, Mitoxantrone, Etoposide, Cytarabine
Description: Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
Study NCT00780104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin + MEC
Description: Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
Study NCT04655768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palmar Plate Fixation
Description: Patients are treated by surgery (palmar plate)
Study NCT05302102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral plyometric training
Description: The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
Study NCT05302102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral plyometric training
Description: The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
Study NCT05302102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
Study NCT01673425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine
Description: All participants will be given FluMist.
Study NCT01184339 — intervention group
Intervention type: DEVICE
Intervention: MicroPhage S. aureus/MSSA/MRSA Blood Culture Test
Description: In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test.
Study NCT03403478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LICE
Description: No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
Study NCT03403478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICE
Description: The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running.
Study NCT03403478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIE
Description: The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running.
Study NCT03403478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training
Description: The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics.
Study NCT03335397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-learning application
Description: Mobile application with interactive contents available for android platform and Apple's operating system.
Study NCT03335397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional learning process
Description: Traditional content available in university library.
Study NCT04420208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Pap test
Description: Adding a non-painful step after the most uncomfortable phase of Pap smear
Study NCT04027036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine in reduced doses
Description: contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age
Study NCT01716949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks